Current aspects of the pathogenesis and prevention of preeclampsia
https://doi.org/10.30629/0023-2149-2023-101-12-651-656
Abstract
One of the most dangerous complications of pregnancy is preeclampsia. For effective prevention of preeclampsia, it is necessary to understand its mechanisms of development clearly. The analysis of modern patterns of preeclampsia cause and development are reviewed in this article. There are also the evidences of more effective strategies of prevention preeclampsia in our review, which have proven themselves most of all. The generalized endothelial mother’s disfunction is in the base of preeclampsia pathogenesis and caused by placental factors, genetical susceptibility and the lack of arterial invasion in trophoblast’s cell hereupon it increases the oxidative stress and inflammatory process, leading to complications of mother and fetus. More accurate understanding of preeclampsia mechanisms allows us to correct the adverse of lifestyle of patients and highlight those who are in the group of PE risk and need the prophylaxis to be prescribed. Nowadays, acetylsalicylic acid is a commonly accepted therapeutic medication and reliably effective (optimal dose from 75 to 162 mg). It is prescribed as the prevention from 11th to 14th week.
About the Authors
Yu. V. Shkurenko
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russia (Sechenov University)
Russian Federation
Russian Federation
Yuliya V. Shkurenko — obstetrician-gynecologist, Assistant of the Department of Nursing
119991, Moscow
A. D. Ibatov
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russia (Sechenov University)
Russian Federation
Russian Federation
Alexey D. Ibatov — Doctor of Medical Sciences, Head of the Department of Nursing
119991, Moscow
S. Yu. Trofimova
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russia (Sechenov University)
Russian Federation
Russian Federation
Svetlana Yu. Trofimova — 6th year student at the Clinical Institute of Children's Healthcare
119991, Moscow
References
1. Queensland Clinical Guideline: Hypertension and pregnancy. 2021. P. 3. URL: www.health.qld.gov.au/qcg
2. Atamamen T.F., Naing N.N., Oyetunji J.A., Wan-Arfah N. Systematic literature review on the neonatal outcome of preeclampsia. Pan African Medical Journal. 2022;41:82. DOI: 10.11604/pamj.2022.41.82.31413
3. Rolnik D.L., Nicolaides K.H., Poon L.C. Prevention of preeclampsia with aspirin. American Journal of Obstetrics and Gynecology. 2022;226(2):1108–1119. DOI: 10.1016/j.ajog.2020.08.045
4. Sinkey R.G., Battarbe A.N., Bello N.A., Ives C.W., Oparil S., Tita A.T.N. Prevention, Diagnosis and Management of Hypertensive Disorders of Pregnancy: A Comparison of International Guidelines. Current Hypertension Reports. 2020;22(9):66. DOI: 10.1007/s11906-020-01082-w
5. Ma’ayeh M., Costantine M.M. Prevention of preeclampsia. Seminars in Fetal Neonatal Medicine. 2020;25(5):101123. DOI: 10.1016/j.siny.2020.101123
6. Garovic V.D. White W.M., Vaughan L., Saiki M., Parashuram S., Garcia-Valencia O. Incidence and Long-Term Outcomes of Hypertensive Disorders of Pregnancy. Journal of the American College of Cardiology. 2020;75(18):2323–2334. DOI: 10.1016/j.jacc.2020.03.028
7. Ives C.W., Sinkey R., Rajapreyar I., Tita ATN, Oparil S., Preeclampsia — Pathophysiology and Clinical Presentations. Journal of the American College of Cardiology. 2020;76(14):1690–1702. DOI: 10.1016/j.jacc.2020.08.014
8. Tomimatsu T., Mimura K., Matsuzaki S., Endo M., Kumasawa K., Kimura T. Preeclampsia: Maternal Systemic Vascular Disorder Caused by Generalized Endothelial Dysfunction Due to Placental Antiangiogenic Factors. International Journal of Molecular Sciences. 2019;20(17):4246. DOI: 10.3390/ijms20174246
9. Burton G.J., Redman C.W., Roberts J.M., Moff ett A. Pre-eclampsia: pathophysiology and clinical implications. BMJ. 2019;366:l2381. DOI: 10.1136/bmj.l2381
10. Ridder A., Giorgione V., Khalil A., Thilaganathan B. Preeclampsia: the relationship between uterine artery blood flow and trophoblast function. International Journal of Molecular Sciences. 2019;20(13):3263. DOI: 10.3390/ijms20133263
11. Staff A.C. The two-stage placental model of preeclampsia: An update. Journal of Reproductive Immunology. 2019;134–135:1–10. DOI: 10.1016/j.jri.2019.07.004
12. Redman C.W.G., Staff A.C. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. American Journal of Obstetric and Gynecology. 2015;213(4):S9.e1,S9–11. DOI: 10.1016/j.ajog.2015.08.003
13. Wang Y., Li B., Zhao Y. Inflammation in preeclampsia: genetic biomarkers, mechanisms, and therapeutic strategies. Frontiers in Immunology. 2022;13:883404. DOI: 10.3389/fimmu.2022.883404
14. Garrido-Gómez T., Castillo-Marco N., Cordero T., Simon C. Decidualization resistance in the origin of preeclampsia. American Journal of Obstetric and Gynecology. 2022;226(2):S886–S894. DOI: 10.1016/j.ajog.2020.09.039
15. Michalczyk M., Celewicz A., Celewicz., Wozniakowska-Gondek P., Rzepka R. The role of inflammation in the pathogenesis of preeclampsia. Mediators Inflammation. 2020;2020:3864941. DOI: 10.1155/2020/3864941
16. Nakashima A., Shima T., Tsuda S., Aoki A., Kawaguchi M., Furuta A., Aggrephagy deficiency in the placenta: a new pathogenesis of preeclampsia. International Journal of Molecular Sciences. 2021;22(5):2432. DOI: 10.3390/ijms22052432
17. Wang Z., Zhao G., Zeng M., Feng W., Liu J. Overview of extracellular vesicles in the pathogenesis of preeclampsia. Biology Reproduction. 2021;105(1):32–39. DOI: 10.1093/biolre/ioab060
18. Guerby P., Tasta O., Swiader A., Pony F., Bujold E., Parant O. Role of oxidative stress in the dysfunction of the placental endothelial nitric oxide synthase in preeclampsia. Redox Biology. 2021;40:101861.18. DOI: 10.1016/j.redox.2021.101861
19. Matsubara K., Matsubara Y., Uchikura Y., Sugiyama T. Pathophysiology of preeclampsia: the role of exosomes. International Journal of Molecular Sciences. 2021;22(5):2572. DOI: 10.3390/ijms22052572
20. Staff A.C., Fjeldstad H.E., Fosheim I.K., Moe K., Turowski G., Johnsen G.M. Failure of physiological transformation and spiral artery atherosis: their roles in preeclampsia. American Journal of Obstetrics and Gynecology. 2022;226(2):895–906. DOI: 10.1016/j.ajog.2020.09.026
21. Szilagyi A., Gelencser Z., Romero R., Xu Y., Kiraly P., Demeter A. Placenta-specific genes, their regulation during villous trophoblast differentiation and dysregulation in preterm preeclampsia. International Journal of Molecular Sciences. 2020;21(2):628. DOI: 10.3390/ijms21020628
22. Wang X., Sun T., Chen G., Gao H. Association between vascular endothelial growth factor gene polymorphisms and pre-eclampsia susceptibility: an updated meta-analysis. Immunological Investigations. 2020;49(1–2):120–133. DOI: 10.1080/08820139.2019.1659812
23. Roberts J.M., Rich-Edwards J.W., NcElrath T.F., Garmire L., Myatt L. Subtypes of preeclampsia: recognition and determining clinical usefulness. Hypertension. 2021;77(5):1430–1441. DOI: 10.1161/hypertensionaha.120.14781
24. Vishnyakova P., Poltavets A., Nikitina M., Muminova K., Potapova A., Vtorushina V. Preeclampsia: inflammatory signature of decidual cells in early manifestation of disease. Placenta. 2021;104:277–283. DOI: 10.1016/j.placenta.2021.01.011
25. Angeli F., Angeli E., Trapasso M., Verdecchia P. Pentraxin-3 and the pathogenesis of preeclampsia. Hypertension Research. 2020;43(9):979–981. DOI: 10.1038/s41440-020-0466-5
26. Wang S., Chen C., Sun F., Li M., Du M., Li X. Involvement of the Tim-3 pathway in the pathogenesis of pre-eclampsia. Reproductive Sciences. 2021;28(12):3331–3340. DOI: 10.1007/s43032-021-00675-3
27. Veisani Y., Jenabi E., Delpisheh A., Khazaei S. Angiogenic factors and the risk of preeclampsia: а systematic review and meta-analysis. International Journal of Reproductive BioMedicine. 2019;17(1):1–10. DOI: 10.18502/ijrm.v17i1.3815
28. Wright D., Wright A., Nicolaides K.H. The competing risk approach for prediction of preeclampsia. American Journal of Obstetrics and Gynecology. 2020;223(1):12–23.e7. DOI: 10.1016/j.ajog.2019.11.1247
29. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222. Obstetrics and Gynecology. 2020;135(6):1492–1495. DOI: 10.1097/aog.0000000000003892
30. Jena M.K., Sharma N.R., Petitt M., Maulik D., Nayak N.R. Pathogenesis of preeclampsia and therapeutic approaches targeting the placenta. Biomolecules. 2020;10(6):953. DOI: 10.3390/biom10060953
31. Robertson S.A. Preventing preeclampsia by silencing soluble Flt-1? New England Journal of Medicine. 2019;380(11):1080–1082. DOI: 10.1056/nejmcibr1817501
32. Wright D., Wright A., Tan M.Y., Nicolaides K.H. When to give aspirin to prevent preeclampsia: application of Bayesian decision theory. American Journal of Obstetrics and Gynecology. 2022;226(2):1120–1125. DOI: 10.1016/j.ajog.2021.10.038
33. Duley L., Meher S., Hunter K.E., Seildler A.L., Askie L.M. Antiplatelet agents for preventing pre‐eclampsia and its complications. The Cochrane Database of Systematic Reviews. 2019;2019(10). DOI: 10.1002/14651858.cd004659.pub3
34. Foisy M.A., Marchant I., Lessard L., Caron L., Bujold E. Aspirin for the prevention of preeclampsia. Journal of Perinatal Medicine. 2022;50(9):1271–1272. DOI: 10.1515/jpm-2022-0301
35. LeFevre M.L., Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine. 2014;161(11):819–826. DOI: 10.7326/m14-1884
36. Shen L., Martinez-Portilla R.J., Rolnik D.L., Pool L.C. ASPRE trial: risk factors for development of preterm pre-eclampsia despite aspirin prophylaxis. Ultrasound in Obstetrics and Gynecology. 2021;58(4):546–552. DOI: 10.1002/uog.23668
37. Poniedziałek-Czajkowska E., Mierzynski R., Dluski D., Leszczynska-Gorzelak B. Prevention of hypertensive disorders of pregnancy-is there a place for metformin. Journal of Clinical Medicine. 2021;10(13):2805. DOI: 10.3390/jcm10132805
38. Fogacci S., Fogacci F., Banach M., Michos E.D., Hernandez A.V., Lip G.Y.H. Vitamin D supplementation and incident preeclampsia: A systematic review and meta-analysis of randomized clinical trials. Clinical Nutrition. Elsevier. 2020;39(6):1742–1752. DOI: 10.1016/j.clnu.2019.08.015
39. Ma’ayeh M., Rood K.M., Kniss D., Constantine M.M. Novel interventions for the prevention of preeclampsia. Current Hypertension Reports. 2020;22(2):17. DOI: 10.1007/s11906-020-1026-8
40. Gu S., Zhou C., Pei J., Wu Y., Wan S., Zhao X. Esomeprazole inhibits hypoxia/endothelial dysfunction-induced autophagy in preeclampsia. Cell and Tissue Research. 2022;388(1):181–194. DOI: 10.1007/s00441-022-03587-z
41. Smith D.D., Costantine M.M. The role of statins in the prevention of preeclampsia. American Journal of Obstetrics and Gynecology. 2022;226(2):1171–1181. DOI: 10.1016/j.ajog.2020.08.040
42. Shu C., Han S., Xu P., Wang Y., Cheng T., Hu C. Estrogen and preeclampsia: potential of estrogens as therapeutic agents in preeclampsia. Drug Design, Development and Therapy. 2021;15:2543–2550. DOI: 10.2147/dddt.s304316
Review
For citations:
Shkurenko Yu.V., Ibatov A.D., Trofimova S.Yu. Current aspects of the pathogenesis and prevention of preeclampsia. Clinical Medicine (Russian Journal). 2023;101(12):651-656. (In Russ.) https://doi.org/10.30629/0023-2149-2023-101-12-651-656
Views:
443
Email this article 